SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy.

The drug research was originally carried out by the Children’s Hospital of Philadelphia (CHOP), the world’s leading centre for leukodystrophy research, under a sponsored research agreement.

CHOP identified a candidate antisense oligonucleotide (ASO) as a potential therapy for H-ABC.

This extension to the companies’ collaboration agreement will see Evotec significantly broaden the pipeline with additional ASOs as candidate therapies.

Dan Williams, CEO at SynaptixBio, said; “The contract with Evotec is absolutely vital for us to ensure we have a range of viable candidates to take through further testing. Not only do they have the capabilities to identify and develop candidate drugs, they can then help us take them right through clinical trials and beyond. They are instrumental in supporting us as we prepare for those clinical trials.”

ASOs work by stopping a gene, in this case the mutated TUBB4A gene, from forming toxic proteins, so it is a type of gene-silencing. A mutated TUBB4A gene results ultimately in less myelin for insulating nerve fibres in the brain, leading to disruption of the signals between neurons.

The US Food and Drug Administration (FDA) recently awarded SynaptixBio a second Orphan Drug Designation (ODD), to allow research and development of a therapy for another form of TUBB4A leukodystrophy, isolated hypomyelination.

The company received its first ODD in early 2023 for the CHOP therapeutic that targets H-ABC.

In October 2023, SynaptixBio was awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease.

Diana Spencer, Senior Digital Content Editor, DDW